Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury

2014/04/01 by Mercedes Robles‐Díaz, Mercedes Robles–Diaz, M. Isabel Lucena +23 · 27 citations
Pharmacology, Toxicology and Pharmaceutics · Medicine · #Drug-Induced Hepatotoxicity and Protection #Liver Disease Diagnosis and Treatment #Pharmacogenetics and Drug Metabolism

paper · pdf · doi:10.1053/j.gastro.2014.03.050

Citations

• Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period
• Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States
• Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States

Cited by

• Beyond Hy's Law: Importance of Markedly Elevated Aminotransferases without Hyperbilirubinemia
• Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases
• Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. [europepmc]
• Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model. [europepmc]
• The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. [europepmc]
• Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. [europepmc]
• Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. [europepmc]
• Biomarkers in DILI: One More Step Forward. [europepmc]
• Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. [europepmc]
• Drug-induced liver injury. [europepmc]
• Drug-induced liver injury: recent advances in diagnosis and risk assessment. [europepmc]
• Death and liver transplantation within 2 years of onset of drug-induced liver injury. [europepmc]
• Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. [europepmc]
• Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy. [europepmc]
• Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. [europepmc]
• A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. [europepmc]
• Traditional Chinese Medicine and Herb-induced Liver Injury: Comparison with Drug-induced Liver Injury. [europepmc]
• Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. [europepmc]
• Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome. [europepmc]
• Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p. [europepmc]
• Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. [europepmc]
• Drug-Induced Liver Injury in GI Practice. [europepmc]
• Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis. [europepmc]
• Recent updates on the management of autoimmune hepatitis. [europepmc]
• Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. [europepmc]
• A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. [europepmc]
• Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. [europepmc]